Northwest Biotherapeutics Inc (NWBO) : Bouchey Financial Group Ltd has sold out all of its stake in Northwest Biotherapeutics Inc during the most recent quarter, according to the disclosure filed by the company on Oct 11, 2016 with the SEC. The investment management company has sold out 13,018 shares of Northwest Biotherapeutics Inc which is valued at $5,962.
Other Hedge Funds, Including , Cutler Group Lp reduced its stake in NWBO by selling 26,796 shares or 98.3% in the most recent quarter. The Hedge Fund company now holds 463 shares of NWBO which is valued at $212.Simplex Trading boosted its stake in NWBO in the latest quarter, The investment management firm added 2,400 additional shares and now holds a total of 3,621 shares of Northwest Biotherapeutics Inc which is valued at $1,528.Telemus Capital boosted its stake in NWBO in the latest quarter, The investment management firm added 17,909 additional shares and now holds a total of 32,401 shares of Northwest Biotherapeutics Inc which is valued at $14,256.
Northwest Biotherapeutics Inc opened for trading at $0.4659 and hit $0.57 on the upside on Tuesday, eventually ending the session at $0.495, with a gain of 8.15% or 0.0373 points. The heightened volatility saw the trading volume jump to 38,51,278 shares. Company has a market cap of $56 M.
Northwest Biotherapeutics Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. The Company’s platform technology DCVax uses activated dendritic cells to mobilize a patient’s own immune system including T cells B cells and antibodies and natural killer cells among others to attack cancer cells. DCVax is designed to target a set of biomarkers on the patient’s tumor. DCVax product lines are made from the patient’s own dendritic cells which are freshly isolated and matured and activated. The Company’s DCVax product lines include DCVax-L DCVax-Direct and DCVax-Prostate. DCVax-L is made with cancer antigens from tumor lysate. DCVax-Direct incorporates a set of tumor antigens in situ. DCVax-Prostate product line is developed based on the antigen PSMA (Prostate Specific Membrane Antigen) which is found on all late stage prostate cancers.